Arena Pharmaceuticals shares rise on weight loss drug patent

April 7, 2015

Shares of Arena Pharmaceuticals rose Tuesday after the drug developer said it received an additional patent for its weight loss drug Belviq.

Arena and its partner Eisai said approval was granted from the US Patent and Trademark Office. The patent can prevent other companies from producing a similar drug. The patent is expected to last until 2033, Arena CEO Jack Lief said in a written statement.

Belviq is designed to stimulate serotonin receptors in the brain, making patients feel full. The drug first went on sale in 2013.

San Diego-based Arena Pharmaceuticals Inc. makes and developed Belviq, while Eisai Inc., the U.S. unit of Japanese health company Eisai Co., markets the drug.

Arena shares rose 23 cents, or 5.3 percent, to $4.59 in morning trading Tuesday. Its shares are down 28 percent over the past year.

Explore further: Weight loss drug Belviq gets overdue US launch

Related Stories

Weight loss drug Belviq gets overdue US launch

June 7, 2013
Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators.

FDA clears Novo Nordisk's weight loss drug Saxenda

December 23, 2014
The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.

FDA approves weight-loss drug Contrave (Update)

September 11, 2014
U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

US clears first new weight-loss pill in 13 years

June 27, 2012
(AP) — The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

Pfizer painkiller gets longer patent protection (Update)

March 5, 2013
Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...

FDA panel backs Novo Nordisk injection for obesity

September 11, 2014
Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.

Recommended for you

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

Prescription drug monitoring programs may have negative unintended consequences

May 7, 2018
Prescription drug monitoring programs (PDMPs) are a key component of the President's Prescription Drug Abuse Prevention Plan and considered a critical tool for reducing prescription opioid-related illness and death. The results ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.